Anacetrapib: hope for CETP inhibitors? - Wikidata - wikimedia - TriplyDB

Anacetrapib: hope for CETP inhibitors?

Anacetrapib: hope for CETP inhibitors?

http://www.wikidata.org/entity/Q37734553

about

CETP Inhibition: Past Failures and Future Hopes Macrovascular complication phenotypes in type 2 diabetic patients.Defining the Safety of Anacetrapib, a CETP Inhibitor, in Patients at High Risk for Coronary Heart Disease: the DEFINE study.Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.Novel strategies for managing dyslipidemia: treatment beyond statins.Emerging drugs for hyperlipidaemia: an update.

P2860

Q26753158-685DE8F3-2137-4E68-A16C-C0316031BCD2 Q36572131-163FAFDA-4AFA-491D-9588-1675392A8F4D Q37162650-3C28681A-C533-478D-B00C-E4904B1D4467 Q38051303-46763DB6-5D74-4E35-870A-AA0BE70AF673 Q38074335-E1CA3226-E144-4553-80E8-42A61428FB5A Q38263909-D0D639E4-4803-4DBD-93C5-083AA26A9DC7

P2860

Anacetrapib: hope for CETP inhibitors?

http://www.wikidata.org/entity/Q37734553

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 April 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Anacetrapib: hope for CETP inhibitors?

@en

Anacetrapib: hope for CETP inhibitors?

@nl

type

label

Anacetrapib: hope for CETP inhibitors?

@en

Anacetrapib: hope for CETP inhibitors?

@nl

prefLabel

Anacetrapib: hope for CETP inhibitors?

@en

Anacetrapib: hope for CETP inhibitors?

@nl

P1433

Q37734553-8DDECD7E-DB3B-4580-91BE-E8059A82D0E5

P1476

Q37734553-46CB9BE1-FEEB-4A59-B04A-F96BE008C8DF

P2093

Q37734553-339C9F10-E928-4AAD-AB4B-E4AD9539FE98

Q37734553-B50A8C20-A047-4890-86BB-5019DD464E00

P2860

Q37734553-06F9F900-F8C7-4FB4-AB93-89A987F94FEE

Q37734553-12D7E4F1-7569-4172-A613-AA3C05DACD15

Q37734553-21E9B60D-367B-4DB8-8677-C0DE43E66322

Q37734553-260A92D3-BEDF-44AA-AAA3-8A80B011FE18

Q37734553-2D6D5B4A-230B-456D-BD10-2D01A48E6A6A

Q37734553-2DAADAD4-BBB5-472F-9BD6-52C1F96600A4

Q37734553-36D62EEE-03D2-4781-94D1-38E1BD400E94

Q37734553-456992AB-DB1F-443F-8268-046C0791C128

Q37734553-45844F15-203C-407F-A060-C63C43EC6712

Q37734553-520A568D-5609-4579-9A59-DCFD8986AB8C

P304

Q37734553-89806BC0-B421-4ABB-9343-9938411E0011

P31

Q37734553-341540E1-F010-4DD8-95D4-860CB226B99F

P356

Q37734553-3259AFC6-A03A-4960-A838-908DDD47F957

P433

Q37734553-CD7387F4-BAE0-4268-BA73-9E06BAA2CD20

P478

Q37734553-F86F638F-D5D8-48AD-B5C1-748E926BA81C

P577

Q37734553-D73501A0-B601-45CA-9654-FCD2519D82BA

P5875

Q37734553-2AFF0CC1-174E-4740-A827-7311678E59B1

P698

Q37734553-61D6D7D6-BCF8-4A2D-9C46-526D6A11449A

P356

J.1755-5922.2010.00142.X

P1433

Cardiovascular Therapeutics

P1476

Anacetrapib: hope for CETP inhibitors?

@en

P2093

Ronen Gurfinkel

http://www.w3.org/2001/XMLSchema#string

Tisha R Joy

http://www.w3.org/2001/XMLSchema#string

P2860

HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway

Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels

Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin

Effect of torcetrapib on the progression of coronary atherosclerosis

P304

327-339

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1755-5922.2010.00142.X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43226195

http://www.w3.org/2001/XMLSchema#string

P698

20406242

http://www.w3.org/2001/XMLSchema#string